Clot Waveform Analysis for Monitoring Hemostasis

被引:6
作者
Nogami, Keiji [1 ]
机构
[1] Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan
关键词
activated partial thromboplastin time; clot waveform analysis; coagulation; fibrinolysis; hemophilia; HEMOPHILIA-A PATIENTS; PARTIAL THROMBOPLASTIN TIME; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR-VIII ACTIVITY; THROMBIN GENERATION; VERY-LOW; PHENOTYPIC HETEROGENEITY; INTERNATIONAL-SOCIETY; FACTOR-IX; APTT;
D O I
10.1055/s-0042-1756706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clot waveform analysis (CWA) is a recently developed global coagulation assessment, based on the continuous observation of changes in light transmittance, absorbance, or light scattering that occurs as fibrin formed in a plasma sample during routine clotting tests such as activated partial thromboplastin time (aPTT) and prothrombin time (PT). CWA can utilize qualitative waveform patterns as well as sensitive quantitative parameters and can be used as a simple method to assess global hemostasis, and can be applied to various challenging clinical situations. Although not all coagulation analyzers currently in use are able to provide CWA, the number of analyzers available to do so is increasing, as the usefulness of this process has become more widely recognized. CWA can be based on the coagulation mechanism of aPTT, an intrinsic trigger, and this has been reported in many studies, including diagnosis and treatment of patients with hemophilia, disseminated intravascular coagulation, and monitoring of anticoagulants and thrombosis. CWA using trace amounts of tissue factors also has the potential to expand the applications of this technology. Recently, there have been reports of the combined evaluation of fibrinolytic dynamics. Among the existing global coagulation assays, CWA may prove to be the easiest to standardize in clinical practice. However, more extensive testing using standardized methods in various clinical settings is needed to determine the true role of CWA in the evaluation of hemostasis and thrombosis in the future.
引用
收藏
页码:592 / 599
页数:8
相关论文
共 54 条
[1]   Automated screening procedure for the phenotypes of congenital fibrinogen disorders using novel parameters, |min1|c and Ac/|min1|c, obtained from clot waveform analysis using the Clauss method [J].
Arai, Shinpei ;
Kamijo, Tomu ;
Kaido, Takahiro ;
Yoda, Masahiro ;
Shinohara, Sho ;
Suzuki, Takeshi ;
Arai, Nobuo ;
Sugano, Mitsutoshi ;
Uehara, Takeshi ;
Okumura, Nobuo .
CLINICA CHIMICA ACTA, 2021, 521 :170-176
[2]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[3]  
Braun PJ, 1997, THROMB HAEMOSTASIS, V78, P1079
[4]   Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab [J].
Dargaud, Yesim ;
Lienhart, Anne ;
Janbain, Maissaa ;
Le Quellec, Sandra ;
Enjolras, Nathalie ;
Negrier, Claude .
HAEMATOLOGICA, 2018, 103 (04) :E181-E183
[5]   Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis [J].
Downey, C ;
Kazmi, R ;
Toh, CH .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (01) :65-69
[6]   Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation [J].
Downey, C ;
Kazmi, R ;
Toh, CH .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (01) :68-73
[7]  
Fan BE, 2022, J THROMB THROMBOLYS, V53, P646, DOI 10.1007/s11239-021-02575-4
[8]   Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors [J].
Furukawa, Shoko ;
Nogami, Keiji ;
Shimonishi, Naruto ;
Nakajima, Yuto ;
Matsumoto, Taisei ;
Shima, Midori .
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (05) :727-735
[9]   F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis [J].
Gouw, Samantha C. ;
van den Berg, H. Marijke ;
Oldenburg, Johannes ;
Astermark, Jan ;
de Groot, Philip G. ;
Margaglione, Maurizio ;
Thompson, Arthur R. ;
van Heerde, Waander ;
Boekhorst, Jorien ;
Miller, Connie H. ;
le Cessie, Saskia ;
van der Bom, Johanna G. .
BLOOD, 2012, 119 (12) :2922-2934
[10]   Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis [J].
Haku, J. ;
Nogami, K. ;
Matsumoto, T. ;
Ogiwara, K. ;
Shima, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (03) :355-362